The Commonwealth Serum Laboratories was established in Australia in 1916.
At CSL, Corporate Responsibility is about conducting our business ethically.
We offer the broadest range of quality plasma-derived and recombinant therapies in the industry.
Seqirus opened in 2015 and is the second largest influenza company in the world.
Innovation has been in the DNA of CSL since our beginning in 1916
Our product portfolio focuses on innovation in new products
Help us deliver on our promise to save lives and protect the health of people.
Diversity and inclusion are top priorities for CSL.
View our ASX announcements
Visit this page to see all of our current news releases
Nancy Millis building opens at Bio21 Institute
The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of M…
Developments in cell-based vaccine technology
CSL spotlights developments in cell-based vaccine technology at Australian Research and Development briefing
2019 Centenary Fellowship Winners Announced
Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research…
CSL Donates to Indonesian Relief Operations
CSL today announced an AUD$50,000 donation in support of Indonesian earthquake and tsunami relief efforts.
CSL a Top 100 Company for Diversity & Inclusion
Thomson Reuters Includes the Global Biotechnology Leader in its 2018 Top 100 Global Diversity and Inclusion Index
Centenary Fellowship Applications Open
$2.5 Million Funding Available to Australian Biomedical Researchers
CSL Lifts Profit Guidance
CSL Limited today announced a revised profit outlook for fiscal 2018.
World Haemophilia Day
CSL Behring Marks World Haemophilia Day by Shipping Bleeding Disorders Medicines to the World Federation of Haemophilia
1st Patient Enrollment in CSL112 Trial
The AEGIS-II trial will enrol more than 17,000 patients from approximately 1,000 medical centers around the world.
Popular search terms:
Americas
Asia Pacific
Europe
